Page last updated: 2024-12-06

torsemide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Torsemide is a loop diuretic medication used to treat high blood pressure and fluid retention. It is synthesized in a multi-step process involving the reaction of 4-chloro-3-sulfamoylbenzoic acid with 3-amino-4-methyl-1,2-thiazole. It works by blocking the reabsorption of sodium and chloride in the loop of Henle, leading to increased urine output. This effect helps reduce fluid retention and lower blood pressure. Torsemide is a potent diuretic with a long duration of action. It is studied extensively due to its effectiveness in managing various conditions, including congestive heart failure, edema, and hypertension. Its importance lies in its ability to alleviate symptoms and improve the quality of life for individuals suffering from these conditions.'

Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID41781
CHEMBL ID1148
CHEBI ID9637
SCHEMBL ID41184
MeSH IDM0086132

Synonyms (176)

Synonym
BIDD:GT0623
AC-18762
HMS3393L21
AB00514011-09
BRD-K30480208-001-05-2
ac-4464 ,
pw-2132
torasemide n
bm-02015
luprac
jdl-464
sutril
dilutol
gj-1090
unat
toradiur
torocard
torrem
n-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide
ccris 6736
torasemida [inn-spanish]
torasemidum [inn-latin]
3-pyridinesulfonamide, n-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-
torsemide [usan]
torasemide
jdl 464
torsemide
n-(((1-methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
brn 0498515
SPECTRUM_001776
bm 02015
1-isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
ac 4464
demadex
SPECTRUM5_001699
cas-56211-40-6
NCGC00016879-01
BPBIO1_001341
PRESTWICK2_001030
PRESTWICK3_001030
BSPBIO_001219
MLS001424121
AB00514011
smr000466313
MLS000759418
DB00214
demadex (tn)
torasemide (jan/inn)
torsemide (usp)
56211-40-6
D00382
luprac (tn)
NCGC00095141-02
NCGC00095141-01
KBIO2_007392
KBIOGR_000820
KBIO3_003008
KBIO2_002256
KBIO2_004824
KBIOSS_002257
SPECTRUM2_001142
PRESTWICK0_001030
PRESTWICK1_001030
SPECTRUM3_001832
SPECTRUM4_000290
SPBIO_001063
SPBIO_003080
SPECTRUM1505211
BSPBIO_003503
NCGC00095141-03
MLS001165687 ,
MLS001195611
HMS2051L21
n-(isopropylcarbamoyl)-4-(m-tolylamino)pyridine-3-sulfonamide
T2538
1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea
chebi:9637 ,
ac4464 ,
torasemide anhydrous
CHEMBL1148
upcard
bm02.015
bm-02.015
HMS1571M21
HMS1922N05
1-isopropyl-3-[[4-(3-methylanilino)-3-pyridyl]sulfonyl]urea;torsemide
A830961
HMS2098M21
dtxsid2023690 ,
dtxcid203690
tox21_110662
HMS2234N14
CCG-40257
NCGC00016879-04
NCGC00016879-02
NCGC00016879-03
torsemide [usan:usp]
torasemidum
torasemide [inn]
torasemida
unii-w31x2h97fb
w31x2h97fb ,
FT-0630689
NCGC00016879-07
torsemide [mi]
torsemide [usp monograph]
torasemide [who-dd]
torsemide [usp-rs]
torasemide anhydrous [ema epar veterinary]
torsemide [usp impurity]
torasemide [ep monograph]
torsemide [vandf]
torasemide [mart.]
torsemide [orange book]
soaanz
torasemide [jan]
1-isopropyl-3-((4-m-toluidino-3-pyridyl)sulphonyl)urea
S1698
AKOS015894937
gtpl7312
n-({4-[(3-methylphenyl)imino]-1,4-dihydropyridin-3-yl}sulfonyl)propane-2-carbamimidic acid
HMS3373G20
HY-B0247
n-[(isopropylamino)carbonyl]-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide
MLS006010744
NC00238
STL388026
4-[(3-methylphenyl)amino]-n-(propan-2-ylcarbamoyl)pyridine-3-sulfonamide
SCHEMBL41184
NCGC00016879-06
tox21_110662_1
KS-1123 ,
NGBFQHCMQULJNZ-UHFFFAOYSA-N
4-(3-methylanilino)-n-(propan-2-ylcarbamoyl)pyridine-3-sulfonamide
n-(isopropylcarbamoyl)-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide
n-[(propan-2-yl)carbamoyl]-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide
bm02015
Q-201846
bdbm64107
cid_41781
AB00514011_11
AB00514011_10
1-{4-[(3-methylphenyl)amino]pyridine-3-sulfonyl}-3-(propan-2-yl)urea
sr-01000759362
SR-01000759362-5
3-pyridinesulfonamide, n-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-
torsemide, united states pharmacopeia (usp) reference standard
torasemide for system suitability, european pharmacopoeia (ep) reference standard
torasemide anhydrous, european pharmacopoeia (ep) reference standard
torsemide, >=98% (hplc), solid
torasemide anhydrous; 1-(1-methylethyl)-3-[[4-[(3-methylphenyl)amino]pyridin-3-yl]sulfonyl]urea; n-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide
torasemide, anhydrous
HMS3715M21
BCP07286
Q419948
FT-0675300
torsemide (demadex)
HMS3744G19
T72621
torasemide for system suitability
EN300-118719
1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea
torsemide (usan:usp)
c03ca04
torasemide (ep monograph)
n-(isopropylcarbamoyl)-4-((3-methylphenyl)amino)pyridine-3-sulfonamide
torsemide (usp monograph)
torasemidum (inn-latin)
torasemida (inn-spanish)
n-(1-methylethylaminocarbonyl)-4-(3-methyl-phenylamino)-3-pyridinesulfonamide
torsemide (usp-rs)
torasemide anhydrous (ema epar veterinary)
n-((propan-2-yl)carbamoyl)-4-((3-methylphenyl)amino)pyridine-3-sulfonamide
torsemide (usp impurity)
torasemide (mart.)
Z1515385087

Research Excerpts

Overview

Torsemide is a loop diuretic of the pyridine-sulfonylurea class. It inhibits the Na+/K+/2Cl- cotransporter type 2 in the thick ascending loop of Henle, leading to increased excretion of urinary sodium and chloride and associated diuresis.

ExcerptReferenceRelevance
"Torsemide is a loop diuretic that inhibits the Na+/K+/2Cl- cotransporter type 2 in the thick ascending loop of Henle, leading to increased excretion of urinary sodium and chloride and associated diuresis. "( An evaluation of torsemide in patients with heart failure and renal disease.
DeWald, TA; Greene, SJ; Mentz, RJ; Peters, AE, 2022
)
2.5
"Torsemide (torasemide) is a loop diuretic with longer duration of action, decreased susceptibility to diuretic resistance, and adjunctive aldosterone antagonist properties compared with furosemide."( Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease.
Machen, MC; Oyama, MA; Peddle, GD; Reynolds, CA; Singletary, GE; Trafny, DJ, 2012
)
1.5
"Torsemide is a loop diuretic of the pyridine-sulfonylurea class. "( Torsemide: a pyridine-sulfonylurea loop diuretic.
Adams, KF; Blose, JS; Patterson, JH, 1995
)
3.18
"Torsemide is a loop diuretic similar to furosemide, with similar indications. "( Torsemide: a pyridine-sulfonylurea loop diuretic.
Adams, KF; Blose, JS; Patterson, JH, 1995
)
3.18
"torsemide is an effective and well-tolerated diuretic in patients with acute cardiogenic pulmonary edema."( Intravenous torsemide as adjunctive therapy in patients with acute pulmonary edema.
Gratton, M; Stringer, KA; Watson, W; Wolfe, R, 1994
)
1.39
"Torsemide is a diuretic that acts in the thick ascending limb of the loop of Henle. "( The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency.
Brater, DC; Gehr, TW; Kramer, WG; Matzke, GR; Rudy, DW; Sica, DA, 1994
)
1.99
"Torsemide is a new loop diuretic that has shown, in short-term studies, to induce a longer and higher diuretic and natriuretic action than frusemide. "( Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites.
Abecasis, R; Cobas, S; Guevara, M; Miguez, C; Terg, R, 2001
)
2.07
"Torsemide is a new diuretic drug with a profile of action similar to that of furosemide. "( Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine.
Besenfelder, E; Farthing, D; Karnes, HT; March, C; Wells, B, 1990
)
1.97

Effects

Torsemide has high bioavailability, a relatively long half-life, and a prolonged duration of activity. Torsemide does not accumulate in renal failure.

ExcerptReferenceRelevance
"Torsemide has a longer duration of action and does not accumulate in renal failure."( Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients.
Martin, M; Morgera, S; Spies, C; Staegemann, M; Vargas Hein, O; von Heymann, C; Wagner, D, 2005
)
2.49
"Torsemide has predictable absorption compared to furosemide. "( A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease.
Agarwal, R; Saha, C; Vasavada, N, 2003
)
1.76
"Torsemide has a longer duration of action and does not accumulate in renal failure."( Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients.
Martin, M; Morgera, S; Spies, C; Staegemann, M; Vargas Hein, O; von Heymann, C; Wagner, D, 2005
)
2.49
"Torsemide has high bioavailability, a relatively long half-life, and a prolonged duration of activity."( Torsemide: a new loop diuretic.
Fowler, SF; Murray, KM, 1995
)
2.46

Treatment

Torsemide-treated patients had lower ejection fraction and blood pressure. Patients had higher creatinine and natriuretic peptide level compared with furosemide.

ExcerptReferenceRelevance
"The torsemide-treated and combination-treated patients had worse heart function and higher furosemide equivalent."( Can Torsemide and Combination of Loop Diuretics Improve Mortality in Patients with Chronic Heart Failure After Discharge?
Yao, Y; Zhang, J; Zhang, R; Zhang, Y, 2018
)
1.52
"Torsemide-treated patients had lower ejection fraction and blood pressure and higher creatinine and natriuretic peptide level compared with furosemide."( Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial).
Anstrom, KJ; Armstrong, PW; DeVore, AD; Ezekowitz, JA; Hasselblad, V; Hernandez, AF; Mentz, RJ; Metra, M; O'Connor, CM; Schulte, PJ; Tang, WH; Velazquez, EJ; Voors, AA, 2016
)
2.6

Toxicity

ExcerptReferenceRelevance
" The toxic dose that causes a defined hearing loss in 50% of the animals (TD50) was determined."( Quantitative assessment of torasemide ototoxicity.
Klinke, R; Mertens, M, 1988
)
0.27
" There were no untoward adverse reactions with torasemide, and no significant changes in serum electrolytes, liver, renal, or haematological variables."( Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide.
Knauf, H; Mutschler, E, 1994
)
0.29
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Patients were also monitored for adverse effects."( Efficacy and safety of torasemide in children with heart failure.
Ishido, H; Kamiyama, M; Katogi, T; Kobayashi, T; Kyo, S; Masutani, S; Senzaki, H; Taketazu, M, 2008
)
0.35
" Serum concentrations of sodium and uric acid had not changed after torasemide treatment, and there were no serious adverse events that necessitated drug withdrawal."( Efficacy and safety of torasemide in children with heart failure.
Ishido, H; Kamiyama, M; Katogi, T; Kobayashi, T; Kyo, S; Masutani, S; Senzaki, H; Taketazu, M, 2008
)
0.35

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacodynamic effect of a diuretic agent is essentially dependent on its renal elimination characteristics."( The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics.
Knauf, H; Mutschler, E; Spahn, H, 1991
)
0.28
" This was in accordance with the pharmacokinetic behaviour of torasemide and furosemide."( Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver.
Brunner, G; Häcker, W; von Bergmann, K; von Möllendorff, E, 1988
)
0.27
"The pharmacodynamic effects and the pharmacokinetic parameters of torasemide (1-isopropyl-3- ([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) 20 mg and furosemide 40 mg were compared after oral and intravenous administration in 6 healthy volunteers."( Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
Lesne, M, 1988
)
0.27
" There was no significant difference between the plasma levels of torasemide on Days 1, 10 and 21, nor between its elimination half-life on Days 1 and 21."( Diuretic activity, safety and pharmacokinetics of torasemide during chronic treatment in normal subjects.
Ambroes, Y; Dodion, L; Ronflette, I, 1986
)
0.27
" The large component of nonrenal clearance would predict that torasemide would have only minimal accumulation and prolongation of half-life in patients with renal insufficiency, and this proves to be the case."( Pharmacokinetics and pharmacodynamics of torasemide in health and disease.
Brater, DC, 1993
)
0.29
" The elimination half-life (t1/2) of torasemide was unchanged in renal failure, whereas t1/2 of the torasemide metabolites M1, M3, and M5 were markedly prolonged."( Pharmacokinetics of torasemide and its metabolites in end-stage renal disease.
Braun, N; Krämer, BK; Müller, GA; Risler, T; Schwab, A; Strutz, F, 1994
)
0.29
"The pharmacokinetic profile and pharmacodynamic activities of torasemide, a new pyridine sulfonylurea acting on the loop of Henle, are described."( Pharmacokinetics and pharmacodynamics of torasemide in congestive heart failure.
Kramer, WG, 1994
)
0.29
" Total plasma clearance and half-life were not related to renal function and were found to be similar to those of healthy subjects."( The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency.
Brater, DC; Gehr, TW; Kramer, WG; Matzke, GR; Rudy, DW; Sica, DA, 1994
)
0.55
" In spite of a shift of the pharmacodynamic curve to the right in patients with cirrhosis, there was no significant difference in natriuresis."( Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis.
Brater, DC; Green, PK; Kramer, WG; Pound, D; Rudy, D; Schwartz, S, 1993
)
0.53
" Pharmacokinetic analysis revealed dose proportionality when relating area under the concentration curve to dose."( Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency--preliminary evaluation.
Brater, DC; Gehr, T; Greene, PK; Rudy, DR; Sica, DA; Voelker, JR, 1993
)
0.29
" Torasemide reached a lower maximum plasma concentration than furosemide, but the former drug had a longer apparent terminal half-life and lower renal and non-renal clearances."( Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
Bernareggi, A; Buzzelli, G; Carloni, V; Chibbaro, G; Cotrozzi, G; Foschi, M; Gentilini, P; La Villa, G; Laffi, G; Marra, F; Melani, L; Quartini, M; Simoni, A; Tommasi, AC, 1996
)
0.29
" Pharmacokinetic parameters were assessed before and after diuresis."( The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure.
Fisher, ML; Gottlieb, SS; Khatta, M; Kramer, WG; Roffman, D; Wentworth, D, 1998
)
0.52
" All the pharmacokinetic parameters of torasemide, such as total area under the plasma concentration-time curve from time zero to time infinity (AUC), total body clearance (CL), apparent volume of distribution at steady state (Vss), terminal half-life and mean residence time (MRT), were independent of infusion times."( Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits.
Kim, SH; Kim, YC; Ko, SH; Lee, MG, 2004
)
0.32
" Hence, it could be expected that in rats with PCM, some pharmacokinetic parameters of torasemide could be significantly different compared with those in control rats and rats with PCMC; however, they could be not significantly different between control rats and rats with PCMC."( Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition.
Bae, SK; Chung, SJ; Kim, SG; Kwon, JW; Lee, AK; Lee, DY; Lee, I; Lee, MG; Shim, CK, 2004
)
0.32
"A total of 36 healthy volunteers (12, 9, 1, 9, 3, and 2 carriers of CYP2C9 genotypes *1/*1 , *1/*2 , *2/*2 , *1/*3 , *2/*3 , and *3/*3 , respectively) received a single oral dose of 10 mg torsemide for pharmacokinetic and pharmacodynamic analysis."( CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.
Brockmöller, J; Engelhardt, S; Kirchheiner, J; Meineke, I; Tuchen, F; Vormfelde, SV; Zirk, A, 2004
)
0.72
"Pharmacokinetic and pharmacodynamic parameters were evaluated after an intravenous administration of torasemide at a dose of 10 mg/kg to control rats and rats with acute renal failure induced by uranyl nitrate (U-ARF)."( Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats.
Kim, EJ; Lee, AK; Lee, MG, 2003
)
0.32
"After intravenous (at doses of 1, 2, 5, and 10 mg/kg) and oral (at doses of 1, 5, and 10 mg/kg) administration of torasemide, the pharmacokinetic parameters were dose-independent."( Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats.
Kim, JY; Kim, WB; Kim, YC; Kwon, JW; Lee, DY; Lee, MG, 2005
)
0.33
"The pharmacokinetic and pharmacodynamic parameters of torasemide were compared after intravenous administration at a dose of 2 mg/kg to diabetic rats induced by alloxan (DMIA) or streptozotocin (DMIS), and their respective control rats."( Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin.
Kim, SH; Kim, YC; Lee, MG; Oh, EY, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"The major aim of the study was to compare the pharmacokinetic profile of repeated-dose administration of a prolonged-release (PR) formulation of torasemide with that of an immediate-release (IR) dosage."( Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers.
Antonijoan, RM; Ballester, MR; Barbanoj, MJ; Gich, I; Gropper, S; Guglietta, A; Pelagio, P; Santos, B, 2009
)
0.35
" Pharmacodynamic urine evaluations were similar with both formulations, although urine volume and urine electrolyte excretion were lower for the PR formulation in the first hour after administration."( A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation.
Albet, C; Antonijoan, RM; Ballester, MR; Barbanoj, MJ; Gropper, S; Guglietta, A; Puntes, M; Santos, B, 2009
)
0.35
" The pharmacodynamic response of warfarin was assessed by measuring the international normalized ratio (INR) for 5 consecutive days following drug administration."( Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.
Chang, BC; Gwak, HS; Kim, HO; Lee, KE; Lee, NR; Oh, BR; Park, HY, 2013
)
0.78
" Compared with the control group, Cmax and AUC0-∞ of (R)-warfarin in the high and low dose groups were higher, whereas the volume of distribution/bioavailability and clearance/bioavailability were significantly lower (P < 0."( Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.
Chang, BC; Gwak, HS; Kim, HO; Lee, KE; Lee, NR; Oh, BR; Park, HY, 2013
)
0.78
" This study investigated potential pharmacokinetic drug-drug interactions between empagliflozin and hydrochlorothiazide (HCTZ) or torasemide (TOR)."( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015
)
0.42
" Pharmacokinetic parameters of empagliflozin, HCTZ, and TOR were assessed and standard bioequivalence criteria (80%-125%) were applied."( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015
)
0.42
" Geometric mean ratios (90% CIs) for empagliflozin AUC over a uniform dosing interval and Cmax at steady state were 107."( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015
)
0.42
"No pharmacokinetic drug-drug interaction was observed between empagliflozin and HCTZ or TOR."( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015
)
0.42
" Further studies are necessary to evaluate potential pharmacodynamic differences between torasemide formulations and to assess its impact on clinical therapeutics."( Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.
Antonijoan, RM; Ballester, MR; Delgadillo, J; Gich, I; Puntes, M; Roig, E; Santos, B, 2015
)
0.42
" Further efforts in this series led to the discovery of analogs with improved pharmacokinetic profiles."( Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.
Alonso-Galicia, M; Bailey, T; Brochu, RM; de Jesus, RK; Ding, FX; Ehrhart, J; Felix, JP; Garcia, ML; Gu, X; Ha, S; Hampton, C; Hernandez, M; Jiang, J; Kaczorowski, GJ; Owens, K; Pai, LY; Parmee, ER; Pasternak, A; Pio, B; Priest, BT; Roy, S; Shahripour, A; Sullivan, K; Swensen, AM; Tang, H; Teumelsan, N; Thomas-Fowlkes, B; Walsh, SP; Yang, L; Zhou, X; Zhu, Y, 2016
)
0.43
"To assess pharmacokinetic and pharmacodynamic parameters of torasemide in healthy cats, and to investigate the effects of a single administration of torasemide on indicators of diuresis, plasma creatinine concentration, blood pressure, electrolyte concentrations and markers of the renin-angiotensin-aldosterone system (RAAS)."( Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats.
Broeckx, BJG; de Salazar Alcala, AG; Devreese, M; Hellemans, A; Paepe, D; Roche-Catholy, M; Schneider, M; Smets, P; Woehrlé, F, 2022
)
0.72
" Pharmacokinetic parameters were obtained using a noncompartmental analysis, and the clinically effective dose was assessed using a Hill model."( Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats.
Broeckx, BJG; de Salazar Alcala, AG; Devreese, M; Hellemans, A; Paepe, D; Roche-Catholy, M; Schneider, M; Smets, P; Woehrlé, F, 2022
)
0.72
"64 mL/h/kg and mean terminal half-life was 12."( Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats.
Broeckx, BJG; de Salazar Alcala, AG; Devreese, M; Hellemans, A; Paepe, D; Roche-Catholy, M; Schneider, M; Smets, P; Woehrlé, F, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"The risk assessment of organic anion transporting polypeptide (OATP) 1B1-mediated drug-drug interactions (DDIs) is an indispensable part of drug development."( Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions.
Izumi, S; Komori, T; Kusuhara, H; Maeda, K; Nozaki, Y; Sugiyama, Y; Takenaka, O, 2015
)
0.42
" Participants were assigned to receive either tolvaptan combined with torasemide (n = 20) or torasemide monotherapy (n = 20; control group)."( Short-Term Effects of Tolvaptan in Tricuspid Insufficiency Combined with Left Heart Valve Replacement-Caused Volume-Overload Patients: Results of a Prospective Pilot Study.
Jiang, L; Liu, H; Ma, L; Wu, Z; Xu, L; Yuan, F; Zhai, Z; Zhang, J; Zhou, J, 2019
)
0.51

Bioavailability

Torsemide has been shown to have less inter- and intra-individual variation in bioavailability and a longer duration of action compared with furosemide. The bioavailability of torsemide is approximately 80%, with little first-pass metabolism. Torsemide can be given without regard to meals.

ExcerptReferenceRelevance
"5 h in the rat and bioavailability was nearly complete."( Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide.
Delarge, J, 1988
)
0.27
"8 h, its bioavailability after oral administration was 91%, about 25% of the total body clearance was due to renal excretion both after iv."( Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
Lesne, M, 1988
)
0.27
" The pharmacokinetics, absolute bioavailability and metabolic disposition of torasemide have been studied after administration of a standard-release tablet to healthy volunteers."( Pharmacokinetics and metabolism of torasemide in man.
Besenfelder, E; Neugebauer, G; von Möllendorff, E, 1988
)
0.27
" Torasemide was practically fully absorbed by the gastrointestinal tract, its bioavailability by oral route ranged from 80 to 100%."( Pharmacological properties of the new potent diuretic torasemide in rats and dogs.
de Suray, JM; Delarge, J; Denef, J; Georges, A; Gerin, M; Ghys, A; Willems, J, 1985
)
0.27
" administration of 20 mg to six normal volunteers showed good bioavailability (greater than 91%)."( Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect.
Clerckx-Braun, F; Duhoux, P; Lesne, M; van Ypersele de Strihou, C, 1982
)
0.26
" The bioavailability of torsemide is approximately 80%, with little first-pass metabolism, and torsemide can be given without regard to meals."( Torsemide: a pyridine-sulfonylurea loop diuretic.
Adams, KF; Blose, JS; Patterson, JH, 1995
)
2.04
" Torsemide is characterized by good bioavailability and once-daily dosing and, compared with furosemide, provides generally equivalent therapeutic efficacy."( Torsemide: a pyridine-sulfonylurea loop diuretic.
Adams, KF; Blose, JS; Patterson, JH, 1995
)
2.64
" Bioavailability of torsemide was also greater and less variable than that of furosemide."( Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
Black, PK; Brater, DC; Kramer, WG; Serpas, T; Smith, WB; Vargo, DL, 1995
)
0.86
" Absolute bioavailability was essentially 100%."( The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency.
Brater, DC; Gehr, TW; Kramer, WG; Matzke, GR; Rudy, DW; Sica, DA, 1994
)
0.55
" Torsemide was rapidly absorbed with a bioavailability of 96."( Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis.
Brater, DC; Green, PK; Kramer, WG; Pound, D; Rudy, D; Schwartz, S, 1993
)
1.44
" Torasemide is a new loop diuretic that has a high bioavailability of 90% and a plasma half-life of 3-5 hours, which remains unchanged in chronic renal failure."( Torasemide in advanced renal failure.
Kindler, J, 1993
)
0.29
" This is consistent with the high bioavailability demonstrated in previous studies."( Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure.
Black, PK; Brater, DC; Ferguson, J; Grant, AG; Kramer, WG; Serpas, T; Smith, WB, 1996
)
0.62
" It has high bioavailability (> 80%), as does bumetanide, but a longer elimination half-life (3 to 4 hours) than either bumetanide or furosemide (frusemide)."( Benefits and risks of torasemide in congestive heart failure and essential hypertension.
Brater, DC, 1996
)
0.29
" It is well absorbed and yields a bioavailablity of about 80% in healthy individuals, even higher in patients with oedema."( Clinical pharmacokinetics and pharmacodynamics of torasemide.
Knauf, H; Mutschler, E, 1998
)
0.3
" Torasemide also has a high bioavailability and is only slightly influenced by meals in humans."( [Torasemide (LUPRAC): a review of its pharmacological and clinical profile].
Kido, H; Ohtaki, Y, 2001
)
0.31
"Because the bioavailability of oral furosemide is erratic and often incomplete, we tested the hypothesis that patients with heart failure who were treated with torsemide, a predictably absorbed diuretic, would have more favorable clinical outcomes than would those treated with furosemide."( Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure.
Adams, LD; Bennett, SJ; Brater, DC; Deer, MM; Dexter, PR; Ferguson, JA; Lane, KA; Murray, MD; Perkins, SM; Smith, FE; Tierney, WM, 2001
)
0.79
"Torasemide with its more complete and less variable bioavailability offers potential clinical and economic advantages over furosemide in the long-term treatment in patients with CHF."( [Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?].
Falkenstein, P; Follath, F; Gutzwiller, F; Müller, K; Reitberger, U; Spannheimer, A, 2002
)
0.31
" Hence, the extent of absolute oral bioavailability (F) was also independent of oral doses; the values were 95."( Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats.
Kim, JY; Kim, WB; Kim, YC; Kwon, JW; Lee, DY; Lee, MG, 2005
)
0.33
" However, one test product failed to meet the bioequivalence criteria and had a significant initial lower absorption rate profile compared with the reference product (P< or =0."( Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Danilovski, A; Dumić, M; Filić, D; Khan, MZ; Knezević, Z; Radosević, S; Rausl, D, 2006
)
0.33
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
" Torasemide has been developed as a newer type of loop diuretic with a longer half-life, longer duration of action, and higher bioavailability compared to the most commonly used loop diuretic, furosemide."( Torasemide for the treatment of heart failure.
Ishido, H; Senzaki, H, 2008
)
0.35
" However, the PR formulation had a lower rate of absorption (lower C(max) and prolonged t(max))."( A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation.
Albet, C; Antonijoan, RM; Ballester, MR; Barbanoj, MJ; Gropper, S; Guglietta, A; Puntes, M; Santos, B, 2009
)
0.35
" These "in combo" PAMPA data were used to predict the human absolute bioavailability of the ampholytes."( The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
Avdeef, A; Sun, N; Tam, KY; Tsinman, O, 2010
)
0.36
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" It is a high-ceiling diuretic that has a longer half-life, longer duration of action and higher bioavailability compared to furosemide."( [Update: prolonged-release torasemide].
Acuña, C, 2010
)
0.36
" It has higher bioavailability (>80%) and a longer elimination half-life (3 to 4 hours) than furosemide."( [Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension].
Arystanova, A; Khoseva, EN; Nekrasova, NI; Pataraia, SA; Preobrazhenskiĭ, DV; Talyzina, IV, 2011
)
0.37
"Furosemide is the most widely prescribed loop diuretic in the setting of systolic heart failure (HF), yet torsemide has been shown to have less inter- and intra-individual variation in bioavailability and a longer duration of action compared with furosemide."( Should torsemide be the loop diuretic of choice in systolic heart failure?
DiNicolantonio, JJ, 2012
)
1.05
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Mean absolute bioavailability was estimated at 88."( Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats.
Broeckx, BJG; de Salazar Alcala, AG; Devreese, M; Hellemans, A; Paepe, D; Roche-Catholy, M; Schneider, M; Smets, P; Woehrlé, F, 2022
)
0.72

Dosage Studied

The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of torsemide are reviewed. The recommended initial adult dosage is between 5 and 20 mg once daily orally or intravenously. Administration of tor Semide to patients with CHF as a continuous infusion was an effective dosing regimen.

ExcerptRelevanceReference
" In both groups doubling of the dosage was performed in these patients who had an insufficient blood pressure control after 4 weeks."( Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment.
Häcker, W; Schmidt, W; Spieker, C; Vetter, H; Zidek, W, 1988
)
0.27
" Urinary dose-response curves showed torasemide to be five times as potent as furosemide."( Clinical pharmacology of torasemide, a new loop diuretic.
Anderson, SA; Brater, DC; Leinfelder, J, 1987
)
0.27
" Depending on the indication, the recommended initial adult dosage of torsemide is between 5 and 20 mg once daily orally or intravenously."( Torsemide: a pyridine-sulfonylurea loop diuretic.
Adams, KF; Blose, JS; Patterson, JH, 1995
)
1.97
" Torsemide is characterized by good bioavailability and once-daily dosing and, compared with furosemide, provides generally equivalent therapeutic efficacy."( Torsemide: a pyridine-sulfonylurea loop diuretic.
Adams, KF; Blose, JS; Patterson, JH, 1995
)
2.64
"5 to 5 mg/day) in the treatment of hypertension, and have shown it to be effective when administered orally at a dosage of 5 to 20 mg/day in the management of congestive heart failure."( Torasemide. An update of its pharmacological properties and therapeutic efficacy.
Brogden, RN; Dunn, CJ; Fitton, A, 1995
)
0.29
" (n = 6) or single oral (n = 6) dosing of 200 mg torasemide, and during chronic oral treatment for 9 days (n = 12)."( Pharmacokinetics of torasemide and its metabolites in end-stage renal disease.
Braun, N; Krämer, BK; Müller, GA; Risler, T; Schwab, A; Strutz, F, 1994
)
0.29
"This study evaluated the dose-response relationship of torsemide, the first pyridine-sulphonylurea loop diuretic, in patients with ascites due to cirrhosis."( A dose-response study of orally administered torsemide in patients with ascites due to cirrhosis.
Applefeld, JJ; Dukes, GE; Hak, LJ; Kasmer, RJ; McClain, CJ; Wermeling, DP, 1994
)
0.8
" The pharmacokinetics of both intravenous and oral torsemide were linear over the dosage range studied."( The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency.
Brater, DC; Gehr, TW; Kramer, WG; Matzke, GR; Rudy, DW; Sica, DA, 1994
)
0.8
" Although there was no saturation of the urinary excretory pathway with doses as high as 200 mg, the upper plateau of the dose-response curve was reached with doses of 50 mg, indicating that this dose represents a ceiling dose in patients with New York Heart Association class II and III congestive heart failure."( The pharmacodynamics of torsemide in patients with congestive heart failure.
Black, PK; Brater, DC; Kramer, WG; Serpas, T; Smith, WB; Vargo, D, 1994
)
0.6
"In a double-blind dose-response study, 49 patients with New York Heart Association functional class III or IV heart failure were randomized to receive a single intravenous dose of 5, 10, or 20 mg torsemide or 40 mg furosemide."( Dose-response study of intravenous torsemide in congestive heart failure.
Bremner, S; Hariman, RJ; Jones, JP; Kostis, JB; Louie, EK; Nocero, MA; Rogers, WJ, 1994
)
0.75
" On the fourth day of once-daily dosing with hydrochlorothiazide 25 mg, 24-hour natriuresis and chloriuresis are no longer augmented, but the elevation in 24-hour kaliuresis that follows the first dose remains unchanged."( Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.
Leary, WP; Reyes, AJ, 1993
)
0.29
"5 after oral dosing and 1:1 after intravenous administration."( Torasemide in advanced renal failure.
Kindler, J, 1993
)
0.29
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of torsemide are reviewed."( Torsemide: a new loop diuretic.
Fowler, SF; Murray, KM, 1995
)
1.95
" Administration of torsemide to patients with CHF as a continuous infusion was an effective dosing regimen, resulting in 24-hour diuresis and natriuresis that was numerically but not statistically greater than that observed with bolus administration."( Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure.
Black, PK; Brater, DC; Ferguson, J; Grant, AG; Kramer, WG; Serpas, T; Smith, WB, 1996
)
0.95
"Effects, both acute and after repeated dosing of 200 mg of intravenous torasemide in comparison to baseline values on placebo, were investigated with respect to 24 h fractional volume excretion and electrolyte excretion, signs of peripheral edema and changes in body weight in the present open uncontrolled multicenter study."( High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure.
Boesken, WH; Kult, J, 1997
)
0.3
" Consistent with the modulation of enzyme activity by genetic and other factors, wide interindividual variability occurs in the elimination and/or dosage requirements of prototypic CYP2C9 substrates."( Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
Birkett, DJ; Miners, JO, 1998
)
0.3
" A dose-response curve to Ang II was plotted for cumulative concentrations (from 10(-9) to 10(-6) mol/L) in endothelium-denuded aortic rings (pD(2)=7."( Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats.
Díez, J; Fortuño, A; Fortuño, MA; Muñiz, P; Ravassa, S; Rodriguez, JA; Zalba, G, 1999
)
0.3
" Some implications for the bioequivalence evaluation of dosage forms of torasemide are discussed."( Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide.
Kim, SH; Kim, YC; Ko, SH; Lee, MG, 2003
)
0.32
" Three decision trees for solid oral dosage forms or liquid suspensions are provided for evaluating when and how polymorphs of drug substances should be monitored and controlled in ANDA submissions."( Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
Adams, RC; Furness, MS; Gill, DS; Holcombe, FO; Raw, AS; Yu, LX, 2004
)
0.32
" Dosages of 29 (0-160) mg torsemide and a dosage of 60 (0-240) mg furosemide were given every 6 h in each group, respectively."( Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients.
Martin, M; Morgera, S; Spies, C; Staegemann, M; Vargas Hein, O; von Heymann, C; Wagner, D, 2005
)
2.07
"Efficacy of torasemide was significantly higher with bedtime dosing (11."( [Chronotherapy with torasemide in hypertensive patients: increased efficacy and therapeutic coverage with bedtime administration].
Ayala, DE; Calvo, C; Chayán, L; Fernández, JR; Fontao, MJ; Hermida, RC; López, JE; Mojón, A; Rodríguez, M; Soler, R, 2006
)
0.33
"Furosemide and torasemide induce a similar dose-response curve venodilation, but they have no effect on the arterial bed."( Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls.
de Berrazueta, JR; de Mier, I; García-Unzueta, MT; González, JP; Poveda, JJ, 2007
)
0.34
"Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375."( Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.
Fromm, MF; Graf, B; Grosch, A; Lestin, HG; Meybaum, A; Schmidt, B; Umbreen, S; Werner, D; Werner, U; Zolk, O, 2008
)
0.35
" The efficacy of torasemide was significantly greater with bedtime dosing (i."( Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension.
Alonso, I; Ayala, DE; Chayán, L; Domínguez, MJ; Fernandez, JR; Fontao, MJ; Hermida, RC; Mojón, A; Soler, R, 2008
)
0.35
"2), requiring a warfarin dosage reduction."( Probable interaction between warfarin and torsemide.
Bird, J; Carmona, C, 2008
)
0.61
" No levothyroxine dosage changes occurred over the previous 14 months; thus, this also was ruled out as a possible etiology."( Probable interaction between warfarin and torsemide.
Bird, J; Carmona, C, 2008
)
0.61
"For the animal study, rats were orally dosed with warfarin (0."( Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.
Chang, BC; Gwak, HS; Kim, HO; Lee, KE; Lee, NR; Oh, BR; Park, HY, 2013
)
0.78
" The proposed metric-weight loss indexed to diuretic dose-better captures a dose-response relationship."( Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA, 2014
)
0.4
" Geometric mean ratios (90% CIs) for empagliflozin AUC over a uniform dosing interval and Cmax at steady state were 107."( Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Broedl, UC; Heise, T; Macha, S; Mattheus, M; Woerle, HJ, 2015
)
0.42
" Secondary objectives include monitoring of: changes in signs and symptoms of heart failure, NYHA functional class, quality of life, dosage changes, rate of readmissions and mortality."( The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.
Bakuła, E; Balsam, P; Cacko, A; Filipiak, KJ; Fojt, A; Grabowski, M; Główczyńska, R; Huczek, Z; Kowalik, R; Markulis, M; Opolski, G; Ozierański, K; Peller, M; Sieradzki, B; Tymińska, A, 2017
)
0.46
" Objective The aim of this study is to evaluate the impact of torsemide initiation on warfarin dosage requirements."( Evaluation of the effect of torsemide on warfarin dosage requirements.
Lai, S; Momper, JD; Yam, FK, 2017
)
0.99
" Commercially available tablet sizes in North America limit dosing precision, indicating a need to evaluate its strength and stability in suspension."( Long-term Stability of a Compounded Suspension of Torsemide (5 mg/mL) for Oral Administration.
Adin, D; Johnson, PR; Kim, CH; Nguyenba, T; Rosen, S, 2017
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
loop diureticA diuretic that acts on the ascending loop of Henle in the kidney.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
N-sulfonylureaA urea in which one of the hydrogens attached to a nitrogen of the urea group is replaced by a sulfonyl group. The N-sulfonylurea moiety is a key group in various herbicides, as well as in a number of antidiabetic drugs used in the management of type 2 diabetis mellitus.
aminopyridineCompounds containing a pyridine skeleton substituted by one or more amine groups.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Torsemide Action Pathway319

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00790.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency23.93410.007215.758889.3584AID588342
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency3.98110.00137.762544.6684AID914; AID915
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.06900.01237.983543.2770AID1346984; AID1645841
pregnane X nuclear receptorHomo sapiens (human)Potency16.78550.005428.02631,258.9301AID1346982
GVesicular stomatitis virusPotency27.54040.01238.964839.8107AID1645842
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency6.79470.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency30.41720.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency5.69290.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency0.56231.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency6.79471.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)130.70000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)195.00000.160024.4900236.5000AID2382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)AC5032.49800.171030.8718167.9780AID493085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (206)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (61)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (47)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (129)

Assay IDTitleYearJournalArticle
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID118878Tested for anticonvulsant activity by measuring rate of mice protected against electric shock applied at 3 h after injection in maximal electroshock seizure (MES) test; out of 61998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design, synthesis, and anticonvulsant activity of 1-(pyrid-3-ylsulfonamido)-2-nitroethylenes.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID445446Oral bioavailability in human2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID118877Tested for anticonvulsant activity by measuring rate of mice protected against electric shock applied at 0.5 hr after injection in maximal electroshock seizure (MES) test; out of 61998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design, synthesis, and anticonvulsant activity of 1-(pyrid-3-ylsulfonamido)-2-nitroethylenes.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1329981Half life in po dosed human2016Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23
Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID106806Inhibition of malate dehydrogenase (MDH) at 400 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID19664Partition coefficient (logP)1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design, synthesis, and anticonvulsant activity of 1-(pyrid-3-ylsulfonamido)-2-nitroethylenes.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID445445Permeability at pH 6.5 by PAMPA method2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID175814Urinary volume excreted over 4 hr by rats after oral administration of 30 mg/kg1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Design, synthesis, and anticonvulsant activity of 1-(pyrid-3-ylsulfonamido)-2-nitroethylenes.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (403)

TimeframeStudies, This Drug (%)All Drugs %
pre-199047 (11.66)18.7374
1990's106 (26.30)18.2507
2000's117 (29.03)29.6817
2010's92 (22.83)24.3611
2020's41 (10.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 99.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index99.44 (24.57)
Research Supply Index6.28 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index180.94 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (99.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials112 (26.67%)5.53%
Reviews62 (14.76%)6.00%
Case Studies22 (5.24%)4.05%
Observational3 (0.71%)0.25%
Other221 (52.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (33)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure [NCT02087332]Phase 478 participants (Anticipated)Interventional2014-04-30Not yet recruiting
Weight-Based Torsemide Dosing vs. Standard Outpatient Management in Subjects With Heart Failure: A Randomized Open-Label Pilot Study [NCT03187509]Phase 452 participants (Actual)Interventional2018-04-17Completed
Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure [NCT05093621]Phase 3125 participants (Anticipated)Interventional2021-02-08Active, not recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of 20 mg Torsemide Tablets Under Fasting Conditions [NCT00602303]28 participants (Actual)Interventional2003-09-30Completed
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of 20 mg Torsemide Tablets Under Fed Conditions [NCT00602615]28 participants (Actual)Interventional2003-09-30Completed
[NCT02644616]Phase 440 participants (Actual)Interventional2014-11-30Completed
The Effects of Glucocorticoids on Mortality and Renal Function in Patients With Acute Decompensated Heart Failure [NCT00953303]Phase 2/Phase 3102 participants (Actual)Interventional2009-01-31Completed
Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Torsemide Tablets 20mg With That of Roche Demadex 1*20 mg in Healthy Subjects Under Fasting Conditions. [NCT00653549]Phase 126 participants (Actual)Interventional2001-04-30Completed
Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Torsemide Tablets 20mg With That of Roche Demadex 1*20 mg in Healthy Subjects Under Fed Conditions. [NCT00654043]Phase 124 participants (Actual)Interventional2001-04-30Completed
Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD [NCT05171686]Phase 446 participants (Anticipated)Interventional2023-02-01Recruiting
The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial [NCT01942109]Phase 4100 participants (Anticipated)Interventional2013-09-30Recruiting
Randomized Crossover 2 Period Single Dose Bioequivalence Study of 2 Formulations Torasemide Tab. 10mg (Pharmtechnology LLC,Belarus) and Toradiur® Tab. 10mg (MEDA Manufacturing Cologne, Germany) in Healthy Volunteers Under Fasting Conditions [NCT04921566]Phase 126 participants (Actual)Interventional2021-06-05Completed
A Crossover Study of Patients With Heart Failure to Compare Natriuretic Effects of Immediate Release Torsemide vs. Extended Release Torsemide Over 12 Hours After Dosing [NCT06176794]Phase 226 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Randomized, Open-Label, Blinded-Endpoint, Crossover, Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg, in Patients With Compensated Heart Failure (CHF). [NCT01549158]Phase 48 participants (Actual)Interventional2012-02-29Terminated(stopped due to Slow recruitment)
Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension [NCT03354897]Phase 4228 participants (Actual)Interventional2017-04-05Completed
Prospective, Randomised, Open, Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure [NCT00409942]Phase 4142 participants (Actual)Interventional2007-03-31Completed
A Randomized, Balanced, Single Dose, Two-treatment (Fed vs. Fasting), Two-period, Two-sequence, Crossover Study to Evaluate the Effects of Food on the Bioavailability of 60 mg ER Torsemide Tablet in Healthy Human Adult Subjects [NCT03215875]Phase 128 participants (Actual)Interventional2017-10-17Completed
Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study). [NCT00295542]Phase 43,344 participants (Actual)Interventional2000-03-31Completed
Multicentre, Multinational, Parallel, Randomised, Double Blind Clinical Trial, to Evaluate the Non-inferiority of PR Torasemide Versus IR Torasemide in Patients With Mild or Moderate Arterial Hypertension. [NCT00334386]Phase 4388 participants Interventional2005-04-30Completed
Open Label Study for the Functional Characterization of Drug Metabolism and Transport [NCT01788254]Phase 1144 participants (Actual)Interventional2012-01-31Completed
Open Label Repeated Dose Study for the Evaluation of Heritability of and Genetic Influences on Drug Pharmacokinetics (TWINS II) [NCT01845194]Phase 1117 participants (Actual)Interventional2009-12-31Completed
A Two Part, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7145 in Patients With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) [NCT01558674]Phase 111 participants (Actual)Interventional2014-05-23Terminated(stopped due to Lack of efficacy)
A Prospective Controlled Study for the Treatment Effect of Different Intervention Strategies for Pediatric Mitral Regurgitation--A Multicenter Prospective Cohort Study of Innovative Drug Therapy in Improving Left Ventricular Function After Mitral Repair [NCT06039592]164 participants (Anticipated)Observational [Patient Registry]2022-04-01Recruiting
A Comprehensive Research of Pediatric Heart Failure--A Prospective Cohort Study of Drug Therapy for Pediatric Heart Failure [NCT06039540]200 participants (Anticipated)Observational [Patient Registry]2022-01-01Recruiting
A Prospective Controlled Study for the Treatment Effect of Different Intervention Strategies for Pediatric Mitral Regurgitation--A Multicenter Prospective Cohort Study of Innovative Drug Therapy for Pediatric Mitral Regurgitation [NCT06037434]122 participants (Anticipated)Observational [Patient Registry]2022-04-01Recruiting
An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide [NCT03509545]Phase 120 participants (Anticipated)Interventional2021-06-30Recruiting
TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure [NCT03296813]Phase 32,859 participants (Actual)Interventional2018-07-11Completed
A Randomized Controlled Pilot Study for Assessment of Coronary Flow Reserve With Cardiac PET Imaging in Acute Decompensated Heart Failure Patients Treated With Diuretics Versus Ultrafiltration [NCT01457053]4 participants (Actual)Interventional2011-11-30Terminated(stopped due to Population not available for enrollment)
Torsemide for the Prevention of Persistent Postpartum Hypertension in Preeclamptic Women: A Randomized, Placebo-Control Trial [NCT02813551]Phase 2118 participants (Actual)Interventional2016-08-31Completed
Randomized,Open Label,Balanced,Two Treatment, Four Period, Two Sequence, Single Oral Dose, Crossover, Replicate Study Under Fasting Conditions to Test Within Subject Variability of 20mg ER Torsemide and Demadex Tablets in Healthy Adults [NCT03214874]Phase 124 participants (Actual)Interventional2017-06-19Completed
Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between 25 mg BI 10773 and 25 mg Hydrochlorothiazide or 5 mg Torasemide Under Steady State Conditions in Patients With Type 2 Diabetes Mellitus in an Open-label, Randomised, Cross-over Tria [NCT01276288]Phase 123 participants (Actual)Interventional2011-01-31Completed
ESTIA: TorasEmide Induced Effect on Quality of Life and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone. Multicenter, Non-interventional, Prospective, Observational Clinical Study. [NCT06117722]210 participants (Anticipated)Observational2024-01-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01276288 (27) [back to overview]Change in Urinary Excretion in a 24-hour Period of N-terminal Telopeptide (NTx) From Baseline
NCT01276288 (27) [back to overview]Change in Urinary Weight From Baseline
NCT01276288 (27) [back to overview]Change in Urine Osmolality From Baseline
NCT01276288 (27) [back to overview]Change in Urine pH From Baseline
NCT01276288 (27) [back to overview]Maximum Measured Concentration of Empa in Plasma (Cmax, ss)
NCT01276288 (27) [back to overview]Change in Urea Concentration in Urine
NCT01276288 (27) [back to overview]Maximum Measured Concentration of HCT in Plasma (Cmax, ss)
NCT01276288 (27) [back to overview]Maximum Measured Concentration of TOR in Plasma (Cmax, ss)
NCT01276288 (27) [back to overview]Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator
NCT01276288 (27) [back to overview]The Change in Micturition Frequency From the Baseline
NCT01276288 (27) [back to overview]The Change in Total Muscle Sympathetic Nerve Activity (MSNA) From Off- Treatment
NCT01276288 (27) [back to overview]Change in Clearance of Sodium, Potassium, Creatinine, Magnesium, Chloride,Calcium, Phosphate and Uric Acid From Baseline
NCT01276288 (27) [back to overview]Change in Serum Concentration of Renin, Intact Parathyroid Hormone (iPTH) and 1,25-dihydroxyvitamin D From Baseline
NCT01276288 (27) [back to overview]Change in Serum Concentration of Sodium, Potassium, Magnesium, Calcium, Chloride, Phosphate, Glucose and Urea From Baseline
NCT01276288 (27) [back to overview]Change in Urinary Excretion in a 24-hour Period of Sodium, Potassium, Magnesium, Chloride, Calcium, Phosphate, Creatinine, Uric Acid, Glucose From Baseline
NCT01276288 (27) [back to overview]Changes in Bicarbonate Concentrations of Calcium, Bicarbonate Ions and Base Excess in Capillary or Arterialised Blood From Baseline
NCT01276288 (27) [back to overview]Urinary Sodium Excretion Over 24-hour run-in Periods
NCT01276288 (27) [back to overview]Change in pH in Capillary or Arterialised Blood From Baseline
NCT01276288 (27) [back to overview]Area Under the Concentration-time Curve of Empa in Plasma (AUCτ,ss)
NCT01276288 (27) [back to overview]Area Under the Concentration-time Curve of HCT in Plasma (AUCτ,ss)
NCT01276288 (27) [back to overview]Area Under the Concentration-time Curve of TOR in Plasma (AUCτ,ss)
NCT01276288 (27) [back to overview]Change in Body Weight From Baseline
NCT01276288 (27) [back to overview]Change in Serum Concentration of Creatinine and Uric Acid From Baseline
NCT01276288 (27) [back to overview]Change in Serum Concentration of Aldosterone From Baseline
NCT01276288 (27) [back to overview]Change in Serum Concentration of Alkaline Phosphatase (ALP) From Baseline
NCT01276288 (27) [back to overview]Change in Serum Concentration of Fibroblast Growth Factor-23 (FGF- 23) From Baseline
NCT01276288 (27) [back to overview]Change in Serum Osmolality From Baseline
NCT01558674 (7) [back to overview]Change From Baseline in First 24hr Urinary Sodium (UNa) (Part 1)
NCT01558674 (7) [back to overview]Fold Change From Baseline for Serum Creatinine at 24-hours Post Treatment Day 5 Morning Dose (Part 1)
NCT01558674 (7) [back to overview]Apparent Terminal Half-life (t1/2) of MK-7145 (Part 1)
NCT01558674 (7) [back to overview]Area Under the Concentration-time Curve From Time Zero to 24 Hours After Dosing (AUC0-24hr) of MK-7145 (Treatment Days 1 and 5: Part 1)
NCT01558674 (7) [back to overview]Maximum Plasma Concentration (Cmax) of MK-7145 (Treatment Days 1 and 5: Part 1)
NCT01558674 (7) [back to overview]Trough Plasma Concentration (Ctrough) of MK-7145 (Treatment Days 1 and 5: Part 1)
NCT01558674 (7) [back to overview]Time to Cmax (Tmax) of MK-7145(Treatment Days 1 and 5: Part 1)
NCT02813551 (11) [back to overview]Change in Lower Extremity Edema
NCT02813551 (11) [back to overview]Length of Hospital Stay After Delivery
NCT02813551 (11) [back to overview]Number of Participants Requiring Postpartum Readmission
NCT02813551 (11) [back to overview]Number of Participants With Persistent Postpartum Hypertension (Systolic Blood Pressure ≥140 and/or Diastolic Blood Pressure ≥ 90 mmHg)
NCT02813551 (11) [back to overview]Number of Participants With Persistent Postpartum Hypertension (Systolic Blood Pressure ≥140 and/or Diastolic Blood Pressure ≥ 90 mmHg)
NCT02813551 (11) [back to overview]Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg
NCT02813551 (11) [back to overview]Number of Participants With Severe Composite Maternal Morbidity
NCT02813551 (11) [back to overview]Number of Participants With Severe Postpartum Hypertension Requiring Acute Antihypertensives (Systolic Blood Pressure ≥160 and/or Diastolic Blood Pressure ≥ 110 mmHg)
NCT02813551 (11) [back to overview]Number of Participants With Side Effects of Therapy - Decreased Breast Milk
NCT02813551 (11) [back to overview]Number of Participants With Side Effects of Therapy - Hypokalemia (Low Blood Potassium Levels)
NCT02813551 (11) [back to overview]Weight Change

Change in Urinary Excretion in a 24-hour Period of N-terminal Telopeptide (NTx) From Baseline

"Change in urinary excretion in a 24-hour period of N-terminal telopeptide (NTx) from baseline, where baseline was defined as the value obtained from the last 24-hour (h) collection period before the first drug administration in the first treatment period.~The mean change from baseline was evaluated as:~Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,~The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: 24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT

InterventionnM BCE/ mMC (Mean)
Empagliflozin (Empa)6.010
Hydrochlorothiazide (HCT)0.730
Torasemide (TOR)2.030
Empa+ HCT1.380
Empa + TOR3.900

[back to top]

Change in Urinary Weight From Baseline

"Change from baseline in urinary weight in a 24 hour (h)- collection period, where baseline is the last 24-h collection period before first trial drug administration in each treatment period.~The mean change from baseline was evaluated as:~Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,~The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: 24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT

Interventiong/day (Mean)
Empagliflozin (Empa)134.700
Hydrochlorothiazide (HCT)-55.300
Torasemide (TOR)-39.000
Empa+ HCT429.000
Empa + TOR353.200

[back to top]

Change in Urine Osmolality From Baseline

"Change in urine osmolality from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

InterventionmOsm/kg (Mean)
Empagliflozin (Empa)223.15
Hydrochlorothiazide (HCT)-3.900
Torasemide (TOR)-5.800
Empa+ HCT217.700
Empa + TOR330.400

[back to top]

Change in Urine pH From Baseline

"Change in urine pH from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

InterventionpH (Mean)
Empagliflozin (Empa)-0.132
Hydrochlorothiazide (HCT)-0.452
Torasemide (TOR)-0.147
Empa+ HCT-0.448
Empa + TOR0.130

[back to top]

Maximum Measured Concentration of Empa in Plasma (Cmax, ss)

Maximum measured concentration of Empa in plasma (Cmax, ss) at steady state (NCT01276288)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 5 with EMPA alone and on Day 9 with EMPA plus diuretic. The Pre-dose values were averaged over Days 1 to 4 with EMPA alone and on Days 7 & 8 with EMPA plus diuretic

Interventionnmol/L (Geometric Mean)
Empagliflozin (Empa)939
Empa+ HCT1030
Empa + TOR949

[back to top]

Change in Urea Concentration in Urine

"Change in urea concentration in urine from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

Interventionmmol/L (Mean)
Empagliflozin (Empa)-1.515
Hydrochlorothiazide (HCT)67.570
Torasemide (TOR)35.710
Empa+ HCT11.780
Empa + TOR48.690

[back to top]

Maximum Measured Concentration of HCT in Plasma (Cmax, ss)

Maximum measured concentration of HCT in plasma (Cmax, ss) at steady state (NCT01276288)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with HCT alone and on Day 9 with EMPA plus HCT. The Pre-dose values were averaged over Days 1 to 3 with HCT alone and on Days 7 & 8 with EMPA plus HCT

Interventionng/mL (Geometric Mean)
Hydrochlorothiazide (HCT)203
HCT+ Empa205

[back to top]

Maximum Measured Concentration of TOR in Plasma (Cmax, ss)

Maximum measured concentration of Empa in plasma (Cmax, ss) at steady state (NCT01276288)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with TOR alone and on Day 9 with EMPA plus TOR. The Pre-dose values were averaged over Days 1 to 3 with TOR alone and on Days 7 & 8 with EMPA plus TOR

Interventionng/mL (Geometric Mean)
Torasemide (TOR)710
TOR+ Empa741
TOR Metabolite (TOR-M1)42.6
TOR Metabolite (TOR-M3)8.58
TOR-M1+ Empa43.8
TOR-M3 + Empa8.79

[back to top]

Number of Subjects With Clinical Relevant Abnormalities in Vital Signs, Clinical Laboratory Tests, 12-lead Resting Electrocardiogram (ECG), Physical Examination and Assessment of Tolerability by the Investigator

"Number of subjects with clinical relevant abnormalities in vital signs (blood pressure, pulse rate), 12-lead resting electrocardiogram (ECG), clinical laboratory tests (haematology, clinical chemistry, urinalysis, and monitoring of fasting plasma glucose), physical examination and assessment of tolerability by the investigator.~New abnormal findings were reported as Adverse Events (AE). Only Alanine aminotransferase normal under system organ class investigations was determined as an existing AE." (NCT01276288)
Timeframe: From first drug administration until up to 14 days after the last drug administration, up to 35 days

Interventionparticipants (Number)
Empagliflozin (Empa)1
Hydrochlorothiazide (HCT)0
Torasemide (TOR)0
Empa+ HCT0
Empa + TOR0

[back to top]

The Change in Micturition Frequency From the Baseline

For this endpoint the change in total micturition frequency from the baseline was only examined for EMPA where baseline was defined as the day before the first drug administration. (NCT01276288)
Timeframe: Baseline and day 5

Interventionvoids per day (Mean)
Empagliflozin (Empa)1.600

[back to top]

The Change in Total Muscle Sympathetic Nerve Activity (MSNA) From Off- Treatment

The change in total Muscle sympathetic nerve activity (MSNA) that represents an area under the curve of all C-fiber action potentials per minute. This endpoint was evaluated only for Empa. For this endpoint a baseline value was not defined. However, the parameters obtained at 2 measurements time points during the trial were compared. (NCT01276288)
Timeframe: One day before the drug administration, then day 4 after the first drug administration

Interventionaction potentials per min (Mean)
Empagliflozin (Empa)0.241

[back to top]

Change in Clearance of Sodium, Potassium, Creatinine, Magnesium, Chloride,Calcium, Phosphate and Uric Acid From Baseline

"Change in clearance of sodium, potassium, creatinine, magnesium, chloride,calcium, phosphate and uric acid from baseline, where baseline is defined as the value obtained from the last 24-h collection period before the first drug administration in the first treatment period.~The mean change from baseline was evaluated as:~Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,~The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: 24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT

,,,,
Interventionml/min (Mean)
SodiumChloridePotassiumMagnesiumCalciumPhosphateUric AcidCreatinine
Empa + TOR-0.004-0.1172.3240.209-0.1742.3594.359-11.768
Empa+ HCT0.1430.1144.1251.115-0.4072.7955.065-10.126
Empagliflozin (Empa)-0.031-0.1292.0400.398-0.3265.2756.3773.167
Hydrochlorothiazide (HCT)-0.055-0.0582.2051.826-0.2994.633-0.476-7.034
Torasemide (TOR)-0.071-0.157-0.5181.148-0.0654.368-1.310-4.250

[back to top]

Change in Serum Concentration of Renin, Intact Parathyroid Hormone (iPTH) and 1,25-dihydroxyvitamin D From Baseline

"Change in serum concentration of Renin, intact parathyroid hormone (iPTH) and 1,25-dihydroxyvitamin D from baseline , where baseline was defined as the measurement obtained before first drug administration in the first period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

,,,,
Interventionpg/mL (Mean)
ReniniPTH1,25-dihydroxyvitamin D
Empa + TOR17.05012.190-0.970
Empa+ HCT32.7609.280-5.060
Empagliflozin (Empa)-0.9608.2650.230
Hydrochlorothiazide (HCT)16.1506.1601.560
Torasemide (TOR)2.5506.9103.530

[back to top]

Change in Serum Concentration of Sodium, Potassium, Magnesium, Calcium, Chloride, Phosphate, Glucose and Urea From Baseline

"Change in serum concentration of sodium, potassium, magnesium, calcium, chloride, phosphate, glucose and urea from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

,,,,
Interventionmmol/L (Mean)
SodiumPotassiumMagnesiumChlorideCalciumPhosphateUreaGlucose
Empa + TOR1.600-0.3600.1452.100-0.0600.0502.122-0.526
Empa+ HCT-0.100-0.5300.130-3.200-0.0100.1701.504-0.033
Empagliflozin (Empa)1.500-0.1700.1392.050-0.0550.0450.710-1.123
Hydrochlorothiazide (HCT)-0.500-0.4700.025-2.600-0.0400.0600.6500.849
Torasemide (TOR)0.200-0.2000.0591.000-0.080-0.0600.3180.527

[back to top]

Change in Urinary Excretion in a 24-hour Period of Sodium, Potassium, Magnesium, Chloride, Calcium, Phosphate, Creatinine, Uric Acid, Glucose From Baseline

"Change in urinary excretion in a 24-hour period of sodium, potassium, magnesium, chloride, calcium, phosphate, creatinine, uric acid, glucose from baseline, where baseline was defined as the value obtained from the last 24-hour (h) collection period before the first drug administration in the first treatment period. This applies also to sodium excretion in urine, which is additionally obtained one day before the drug administration before the second period.~The mean change from baseline was evaluated as:~Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,~The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: 24 hour sampling interval at baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT

,,,,
Interventionmmol/day (Mean)
SodiumChloridePotassiumMagnesiumCalciumPhosphateCreatinineUric acidGlucose
Empa + TOR1.200-14.6008.4601.050-0.7405.000-0.0401.244740.910
Empa+ HCT28.90011.40015.7902.030-1.3608.3000.0221.555685.233
Empagliflozin (Empa)-4.300-16.30010.3701.190-1.1609.2500.0911.641599.449
Hydrochlorothiazide (HCT)-11.700-12.3006.2002.270-1.0209.000-0.078-0.03717.584
Torasemide (TOR)-13.700-22.000-6.9901.720-0.4304.900-0.073-0.50017.932

[back to top]

Changes in Bicarbonate Concentrations of Calcium, Bicarbonate Ions and Base Excess in Capillary or Arterialised Blood From Baseline

"Changes in bicarbonate concentrations of calcium, bicarbonate ions and base excess in capillary or arterialised blood from baseline, where baseline was defined as the last measurement before trial drug administration of each treatment period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

,,,,
Interventionmmol/ L (Mean)
Bicarbonate concentrations of calciumbicarbonate ionsBase excess
Empa + TOR-1.590-0.049-1.450
Empa+ HCT1.860-0.0531.720
Empagliflozin (Empa)-1.090-0.049-1.045
Hydrochlorothiazide (HCT)2.020-0.0431.640
Torasemide (TOR)-0.400-0.041-0.420

[back to top]

Urinary Sodium Excretion Over 24-hour run-in Periods

Urinary sodium excretion over 24-hour run-in periods to assess the harmonisation of electrolytes after intake of a standardised diet (NCT01276288)
Timeframe: Day 3, 2 and 1 before the first drug administration

,,
Interventionmmol/day (Mean)
3 days before the drug administration2 days before the drug administration1 day before the drug administration
Empagliflozin (Empa)198.50174.35163.90
Hydrochlorothiazide (HCT)211.10183.30170.10
Torasemide (TOR)217.90178.70179.10

[back to top]

Change in pH in Capillary or Arterialised Blood From Baseline

"Change in pH in capillary or arterialised blood from baseline, where baseline was defined as the last measurement before trial drug administration of each treatment period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

InterventionpH (Mean)
Empagliflozin (Empa)-0.006
Hydrochlorothiazide (HCT)0.003
Torasemide (TOR)-0.002
Empa+ HCT0.008
Empa + TOR-0.005

[back to top]

Area Under the Concentration-time Curve of Empa in Plasma (AUCτ,ss)

Area under the concentration-time curve of Empa in plasma at steady state over a uniform dosing interval τ (AUCτ,ss). (NCT01276288)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 5 with EMPA alone and on Day 9 with EMPA plus diuretic. The Pre-dose values were averaged over Days 1 to 4 with EMPA alone and on Days 7 & 8 with EMPA plus diuretic

Interventionnmol*h/L (Geometric Mean)
Empagliflozin (Empa)4990
Empa+ HCT5570
Empa + TOR5260

[back to top]

Area Under the Concentration-time Curve of HCT in Plasma (AUCτ,ss)

Area under the concentration-time curve of HCT in plasma at steady state over a uniform dosing interval τ (AUCτ,ss). (NCT01276288)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with HCT alone and on Day 9 with EMPA plus HCT. The Pre-dose values were averaged over Days 1 to 3 with HCT alone and on Days 7 & 8 with EMPA plus HCT

Interventionng*h/mL (Geometric Mean)
Hydrochlorothiazide (HCT)1040
HCT+ Empa1000

[back to top]

Area Under the Concentration-time Curve of TOR in Plasma (AUCτ,ss)

Area under the concentration-time curve of TOR in plasma at steady state over a uniform dosing interval τ (AUCτ,ss). (NCT01276288)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, and 24 post-dose on Day 4 with TOR alone and on Day 9 with EMPA plus TOR. The Pre-dose values were averaged over Days 1 to 3 with TOR alone and on Days 7 & 8 with EMPA plus TOR

Interventionng*h/mL (Geometric Mean)
Torasemide (TOR)1320
TOR+ Empa1340
TOR Metabolite (TOR-M1)74.8
TOR Metabolite (TOR-M3)40.5
TOR-M1+ Empa78.1
TOR-M3 + Empa41.8

[back to top]

Change in Body Weight From Baseline

"Change in body weight from baseline , where baseline was defined as the last measurement before trial drug administration of each treatment period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

Interventionkg (Mean)
Empagliflozin (Empa)-1.365
Hydrochlorothiazide (HCT)-1.040
Torasemide (TOR)-0.380
Empa+ HCT-2.030
Empa + TOR-1.750

[back to top]

Change in Serum Concentration of Creatinine and Uric Acid From Baseline

"Change in serum concentration of Creatinine and Uric acid from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period~The mean change from baseline was evaluated as:~Empa: day 5- baseline, HCT: day 4-baseline, TOR: day 4-baseline, Empa+ HCT: day 9- baseline, Empa+ TOR: day 9- baseline,~The means for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 5 for Empa, day 4 for TOR and HCT, day 9 for Empa+TOR and Empa+HCT

,,,,
Interventionumol/L (Mean)
CreatinineUric acid
Empa + TOR3.570-48.200
Empa+ HCT6.280-31.000
Empagliflozin (Empa)2.175-64.950
Hydrochlorothiazide (HCT)-0.34024.200
Torasemide (TOR)-2.180-4.700

[back to top]

Change in Serum Concentration of Aldosterone From Baseline

"Change in serum concentration of Aldosterone from baseline , where baseline was defined as the measurement obtained before first drug administration in the first period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

Interventionnmol/L (Mean)
Empagliflozin (Empa)-0.018
Hydrochlorothiazide (HCT)0.099
Torasemide (TOR)0.023
Empa+ HCT0.124
Empa + TOR0.123

[back to top]

Change in Serum Concentration of Alkaline Phosphatase (ALP) From Baseline

"Change in serum concentration of ALP from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

InterventionU/L (Mean)
Empagliflozin (Empa)2.750
Hydrochlorothiazide (HCT)3.000
Torasemide (TOR)2.400
Empa+ HCT6.500
Empa + TOR5.800

[back to top]

Change in Serum Concentration of Fibroblast Growth Factor-23 (FGF- 23) From Baseline

"Change in serum concentration of fibroblast growth factor-23 (FGF- 23) from baseline, where baseline was defined as the measurement obtained before first drug administration in the first period~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline, The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

InterventionRU/mL (Mean)
Empagliflozin (Empa)50.305
Hydrochlorothiazide (HCT)29.050
Torasemide (TOR)-0.680
Empa+ HCT109.860
Empa + TOR13.820

[back to top]

Change in Serum Osmolality From Baseline

"Changes in serum osmolality from baseline based on a blood sample.~Baseline was defined as the measurement obtained before the first drug administration in the first period.~The mean change from baseline was evaluated as:~Empa: day 6- baseline, HCT: day 5-baseline, TOR: day 5-baseline, Empa+ HCT: day 10- baseline, Empa+ TOR: day 10- baseline,~The mean for the Empa arm represent combined adjusted means of all four sequences that is Empa administered before or after the administration of either TOR, HCT and their combination with Empa" (NCT01276288)
Timeframe: baseline and then day 6 for Empa, day 5 for TOR and HCT, day 10 for Empa+TOR and Empa+HCT

InterventionmOsm/Kg (Mean)
Empagliflozin (Empa)3.950
Hydrochlorothiazide (HCT)-7.500
Torasemide (TOR)-5.500
Empa+ HCT-2.200
Empa + TOR10.500

[back to top]

Change From Baseline in First 24hr Urinary Sodium (UNa) (Part 1)

Urine was collected at Treatment Day -1 and Treatment Day 1 at 0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hour. The 24-hour cumulative natriuresis will be estimated by the amount of sodium excreted into urine over 24 hour period postdose, where amount of sodium is the product of sodium concentration and the volume of urine. The change from baseline in UNa from baseline (Treatment Day -1) and 24 hours post-dose on Treatment Day 1 were calculated. (NCT01558674)
Timeframe: Baseline (Day -1) and 0-24 hours postdose on Treatment Day 1 of each treatment period

InterventionmEq (Least Squares Mean)
MK-7145 8 mg (Part 1: Period 1)11.0
Furosemide 40 mg BID (Part 1: Period 2)109.5

[back to top]

Fold Change From Baseline for Serum Creatinine at 24-hours Post Treatment Day 5 Morning Dose (Part 1)

Blood was collected predose on Treatment Day 1 and at 24 hours post morning dose on Treatment Day 5 to determine serum creatinine levels. Creatinine levels were log transformed and then fold change from baseline was calculated. (NCT01558674)
Timeframe: Baseline (predose Treatment Day 1) and 24 hours post morning dose on Treatment Day 5 of each treatment period (Part I)

Interventionmg/dL (Geometric Mean)
MK-7145 8 mg (Part 1: Period 1)1.30
Furosemide 40 mg BID (Part 1: Period 2)1.18

[back to top]

Apparent Terminal Half-life (t1/2) of MK-7145 (Part 1)

Blood samples for pharmacokinetic analysis were collected on Treatment Day 1 through Treatment Day 5 at the following time points: Predose, 3, 5, 6, 8, 10, 12, 14, 18, 24, 96, 101, 104, 106, 108, 110 and 120 hours (relative to Treatment Day 1 dosing). The t1/2 was calculated. (NCT01558674)
Timeframe: Treatment Day 1 and Treatment Day 5

Interventionhours (Median)
Treatment Day 1Treatment Day 5
MK-7145 8 mg (Part 1: Period 1)NANA

[back to top]

Area Under the Concentration-time Curve From Time Zero to 24 Hours After Dosing (AUC0-24hr) of MK-7145 (Treatment Days 1 and 5: Part 1)

Blood samples for pharmacokinetic analysis were collected on Day 4 (Treatment Day 1) through Day 8 (Treatment Day 5) at the following time points: Predose, 3, 5, 6, 8, 10, 12, 14, 18, 24 , 96, 101, 104, 106, 108, 110 and 120 hours (relative to Day 4 dosing). The AUC0-24 was calculated for Days 1 and 5 (NCT01558674)
Timeframe: up to 24 hours post-dose on Treatment Day 1 and Treatment Day 5

InterventionnM*hr (Geometric Mean)
Treatment Day 1Treatment Day 5
MK-7145 8 mg (Part 1: Period 1)158485

[back to top]

Maximum Plasma Concentration (Cmax) of MK-7145 (Treatment Days 1 and 5: Part 1)

Blood samples for pharmacokinetic analysis were collected on Treatment Day 1 through Treatment Day 5 at the following time points: Predose, 3, 5, 6, 8, 10, 12, 14, 18, 24, 96, 101, 104, 106, 108, 110 and 120 hours (relative to Treatment Day 1 dosing). The Cmax was calculated for Treatment Days 1 and 5. (NCT01558674)
Timeframe: Treatment Day 1 and Treatment Day 5

InterventionnM (Geometric Mean)
Treatment Day 1Treatment Day 5
MK-7145 8 mg (Part 1: Period 1)10.226.0

[back to top]

Trough Plasma Concentration (Ctrough) of MK-7145 (Treatment Days 1 and 5: Part 1)

Blood samples for pharmacokinetic analysis were collected on Treatment Day 1 through Treatment Day 5 at the following time points: Predose, 3, 5, 6, 8, 10, 12, 14, 18, 24 , 96 , 101, 104, 106, 108, 110 and 120 hours (relative to Treatment Day 1 dosing). The Ctrough for was calculated for Treatment Days 1 and 5 (NCT01558674)
Timeframe: Treatment Day 1 and Treatment Day 5

InterventionnM (Geometric Mean)
Treatment Day 1Treatment Day 5
MK-7145 8 mg (Part 1: Period 1)NANA

[back to top]

Time to Cmax (Tmax) of MK-7145(Treatment Days 1 and 5: Part 1)

Blood samples for pharmacokinetic analysis were collected on Treatment Day 1 through Treatment Day 5 at the following time points: Predose, 3, 5, 6, 8, 10, 12, 14, 18, 24, 96 , 101, 104, 106, 108, 110 and 120 hours (relative to Treatment Day 1 dosing). The time to Cmax (Tmax) calculated for Treatment Days 1 and 5 (NCT01558674)
Timeframe: Treatment Day 1 and Treatment Day 5

Interventionhours (Median)
Treatment Day 1Treatment Day 5
MK-7145 8 mg (Part 1: Period 1)10.05.0

[back to top]

Change in Lower Extremity Edema

Lower extremity edema was assessed by measuring right ankle circumference at 5 centimeters above the medial malleolus. (NCT02813551)
Timeframe: at the time of randomization (within 24 hours of delivery); at discharge (about 1-5 days after delivery)

Interventionmillimeters (Mean)
Torsemide-1.29
Placebo-2.9

[back to top]

Length of Hospital Stay After Delivery

(NCT02813551)
Timeframe: 0-5 days after delivery

Interventionhours (Median)
Torsemide68
Placebo54

[back to top]

Number of Participants Requiring Postpartum Readmission

(NCT02813551)
Timeframe: 0-6 weeks after delivery

InterventionParticipants (Count of Participants)
Torsemide3
Placebo1

[back to top]

Number of Participants With Persistent Postpartum Hypertension (Systolic Blood Pressure ≥140 and/or Diastolic Blood Pressure ≥ 90 mmHg)

(NCT02813551)
Timeframe: 6 weeks after delivery

InterventionParticipants (Count of Participants)
Torsemide8
Placebo11

[back to top]

Number of Participants With Persistent Postpartum Hypertension (Systolic Blood Pressure ≥140 and/or Diastolic Blood Pressure ≥ 90 mmHg)

(NCT02813551)
Timeframe: 7-10 days after delivery

InterventionParticipants (Count of Participants)
Torsemide9
Placebo11

[back to top]

Number of Participants With Persistent Postpartum Hypertension Defined as Systolic Blood Pressure ≥ 150 and/or Diastolic Blood Pressure ≥ 100 mmHg

Persistent postpartum hypertension was defined as sustained systolic blood pressure ≥ 150 or diastolic blood pressure ≥ 100 mmHg by postpartum day 5 or at hospital discharge, whichever occurred first. (NCT02813551)
Timeframe: 0-5 days after delivery

InterventionParticipants (Count of Participants)
Torsemide26
Placebo34

[back to top]

Number of Participants With Severe Composite Maternal Morbidity

Severe composite maternal morbidity is defined as having any of the following: ICU admission, HELLP syndrome, eclampsia, stroke, renal failure, pulmonary edema, cardiomyopathy, or maternal death. (NCT02813551)
Timeframe: 0-6 weeks after delivery

InterventionParticipants (Count of Participants)
Torsemide0
Placebo0

[back to top]

Number of Participants With Severe Postpartum Hypertension Requiring Acute Antihypertensives (Systolic Blood Pressure ≥160 and/or Diastolic Blood Pressure ≥ 110 mmHg)

(NCT02813551)
Timeframe: 0-6 weeks after delivery

InterventionParticipants (Count of Participants)
Torsemide7
Placebo6

[back to top]

Number of Participants With Side Effects of Therapy - Decreased Breast Milk

(NCT02813551)
Timeframe: 0-5 days after delivery

InterventionParticipants (Count of Participants)
Torsemide1
Placebo0

[back to top]

Number of Participants With Side Effects of Therapy - Hypokalemia (Low Blood Potassium Levels)

(NCT02813551)
Timeframe: 0-5 days after delivery

InterventionParticipants (Count of Participants)
Torsemide1
Placebo4

[back to top]

Weight Change

(NCT02813551)
Timeframe: at the time of randomization (within 24 hours of delivery); at discharge (about 1-5 days after delivery)

Interventionpounds (Mean)
Torsemide3.01
Placebo2.08

[back to top]